SARS-CoV-2 suppression with novel combinatorial AAV-RNAi vectors


News  | BioQuant | May 04th, 2022
Grimm Lab and collaborators at CIID present new recombinant AAV vectors, which inhibit coronavirus infection ex vivo and in vivo. Mol. Ther. 30(5):P2005-2023 (2022)

Read the original publication in Molecular Therapy.

For more information, follow Grimm Lab's Twitter thread.